Point-of-Care Testing
With Clarity and Confidence

Point-of-care testing with SARS-CoV-2,^* Flu A+B, RSV, and Group A Strep assays, providing rapid diagnostic testing in a convenient, portable instrument.

Contact Us

Built for care. Designed to adapt.

Why choose the rapid diagnostic testing of the BD Veritor Plus System?

Versatility

Diagnose multiple respiratory tract infections with the BD Veritor™ Plus System to help minimize their spread as well as reduce their duration.

Reliability

The advanced particle technology of the BD Veritor™ Plus System may improve test performance (when compared to visually read tests) by providing unambiguous professional-grade results.

Connectivity

Optional modules allow the BD Veritor™ Plus System to integrate seamlessly into your EMR/LIS and streamline your workflow to benefit your practice.

Discover how easy sample collection can simplify testing workflows for reliable results you can act on

Point-of-care rapid diagnostic testing has become increasingly essential, and the BD Veritor™ Plus System can make a big difference. In-house respiratory tract infection testing with reliable, rapid results means staff is more prepared for rapid triage; able to detect and diagnose infections and even treat a patient in the same visit.

As a community organization, you have many priorities, but we know you have people to protect. You require flexibility, simplicity and reliability, so that those you serve and those who work for you can continue to enjoy life. With the BD Veritor™ Plus System, you can identify certain respiratory infections and then take steps to limit the spread of these respiratory infections throughout your organization and the community.

Trust BD for the Digital Difference

Integrating workflows for reliable results you can act on.

Unambiguous, easy-to-read results displayed on a digital screen

A portable instrument, about the size of a smartphone

Maintenance-free and calibration-free instrumentation

Operational flexibility to meet your team’s workflow needs

Seamless results management and reporting via optional connectivity solutions

A rechargeable battery for up to 8 hours of continuous testing

Rapid results for multiple respiratory tract infections delivered in 15 minutes or less for increased efficiency

Single-button functionality to easily switch between operating modes

Simplified staff training and ongoing support with comprehensive training resources

Contact Now

Contact a Sales Representative to get your organization’s

diagnostic testing program started today

Useful Documents

BD Veritor™ Plus System Overview Brochure

Download

Professional Care Testing

The BD Veritor™ Plus System enhances point-of-care testing for SARS-CoV-2,* Flu A+B, RSV, and Group A Strep assays, providing rapid diagnostic testing in a convenient, portable instrument.

Learn more

Get Support

See how BD supports you with tools, education, and training—enabling a streamlined point-of-care experience for those you serve, and confidence in your results.

Get support

* The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.

This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.

RSV=respiratory syncytial virus; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.

This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Point-of-Care Testing With Clarity and Confidence